-
-
-
-
-
-
-
ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) from CRT Pioneer Fund, UK
-
-
-
-
-
-
-
ProNAi Reports 2015 Year-End Financial and Operational Results
-
-
1,161,097 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

